Display options
Cite
Yang F, Zhou J, Bo Y, et al. A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. J Sep Sci. 2021;44(5):945-953doi: 10.1002/jssc.202001023.
Yang, F., Zhou, J., Bo, Y., Yin, H., Liu, X. H., & Li, J. (2021). A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. Journal of separation science, 44(5), 945-953. https://doi.org/10.1002/jssc.202001023
Yang, Fen, et al. "A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor." Journal of separation science vol. 44,5 (2021): 945-953. doi: https://doi.org/10.1002/jssc.202001023
Yang F, Zhou J, Bo Y, Yin H, Liu XH, Li J. A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. J Sep Sci. 2021 Mar;44(5):945-953. doi: 10.1002/jssc.202001023. Epub 2021 Jan 18. PMID: 33340437.
Copy Download .nbib Format: NLM
Share it on

J Sep Sci. 2021 Mar;44(5):945-953. doi: 10.1002/jssc.202001023. Epub 2021 Jan 18.

A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor.

Journal of separation science

Fen Yang, Jun Zhou, Yunhai Bo, Han Yin, Xiao Hong Liu, Jian Li

Affiliations

  1. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), National drug clinical trial center, Peking University Cancer Hospital & Institute, Beijing, P. R. China.
  2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, P. R. China.

PMID: 33340437 DOI: 10.1002/jssc.202001023

Abstract

TQ-B3203 is a new topoisomerase I inhibitor derived from camptothecin. In this paper, a simple and reliable ultra high-performance liquid chromatography-tandem mass spectrometric method was developed and validated for determination of TQ-B3203 in human plasma with TQ-B3203-d

© 2021 Wiley-VCH GmbH.

Keywords: TQ-B3203; mass spectrometry; pharmacokinetics; solid tumor

References

  1. Wang JC, Kirkegaard K. Annu. Rev. Biochem. 1996;65(1):100-9. - PubMed
  2. Wang J. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002;3:430-40. - PubMed
  3. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998;279:1504-13. - PubMed
  4. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722-6. - PubMed
  5. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 1992;10:16-20. - PubMed
  6. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson SJ, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. 2000;43:3970. - PubMed
  7. Zunino F. Current status and perspectives in the development of camptothecins, Curr. Pharm. Des. 2002;8:2505-20. - PubMed
  8. Adams DJ, Silva MWD, Flowers JL, Kohlhagen G, Pommier Y, Colvin OM, Manikumar G, Wani MC. Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. Cancer. Chemoth. Pharm. 2006;57:135-44. - PubMed
  9. Zhang X, Cao M, Xing J, Liu F, Dong P, Tian X, Xu H, Zhang L, Gu H, Yang L. TQ-B3203, a potent proliferation inhibitor derived from camptothecin. Med. Chem. Res. 2017;26:3395-406. - PubMed
  10. Schubert R. Medical applications of liposomes. Eur. J. Pharm. Biopharm. 2002;54:358-9. - PubMed
  11. Sempkowski M, Locke T, Stras S, Zhu C, Sofou S. Liposome-based approaches for delivery of mainstream chemotherapeutics: preparation methods, liposome designs,therapeutic efficacy. Crit. Rev. Oncog. 2014;19:177-221. - PubMed
  12. Gabizon AA, Shmeeda H, Zalipsky S. Pros and Cons of the Liposome Platform in Cancer Drug Targeting. J. Liposome. Res. 2006;16:175-83. - PubMed
  13. Shuang R, Wang M, Mao J, Zou J, Ping Y. Pharmacokinetics of 10-hydroxycamptothecin-tetrandrine liposome complexes in rat by a simple and sensitive ultra-high performance liquid chromatography with tandem mass spectrometry. J. Sep. Sci. 2020;43(3):569-76. - PubMed
  14. FDA. Guidance for Industry: Bioanalytical Method Validation, 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry - PubMed
  15. European Medicines Agency. Guideline on Bioanalytical Method Validation, 2011. http://www.ema.europa.eu/docs/en_GB/documentlibrary/Scientificguideline/2011/08/WC500109686.pdf. - PubMed
  16. Jiang JF, Li XL, Chen XY, Zhong DF. Role of human liver and intestine esterases in drug design and development. Acta. Pharm. Sin. 2018, 53(2):177-85. - PubMed

MeSH terms

Publication Types

Grant support